N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that Lantheus’ previously announced consent solicitation (the “Solicitation”), with respect to a proposed amendment to the indenture (the “Indenture”) governing the company’s outstanding $250 million in aggregate principal amount of 9.750% Senior Notes due 2017 (the “Notes”), expired at 5:00 p.m., New York City time, on March 14, 2011 (the “Expiration Time”). As of the Expiration Time, $250 million aggregate principal amount of the Notes, representing 100% of the aggregate principal amount of Notes outstanding, validly delivered a duly executed consent (the “Consent”) for the proposed amendment. The consents received exceed the number needed to approve the proposed amendment to the Indenture.
